| 59375-6 |
Medicare non-therapy Part A billing |
- |
^Patient |
RptPeriod |
- |
CMS Assessment |
|
ACTIVE |
Medicare non-therapy Part A billing during assessment period [CMS Assessment] |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
59375-6 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
N |
|
Centers for Medicare and Medicaid Assessment; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Survey |
2.77 |
2.32 |
|
Organizer |
|
|
|
|
|
|
|
|
Release 2.77: TIME_ASPCT: Decision by CMS to update the Timing to RptPeriod from Pt for all CMS Assessments; Previous Releases: Added "billing" to component to make the panel more specific; Updated METHOD to CMS Assessment to use term across CMS instruments as approved by the Clinical LOINC committee;Changed CLASS from SURVEY.MDS to SURVEY.CMS because term is used across CMS assessments |
0 |
| 59376-4 |
3-Keto, 2-Methylvalerate/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
3-Keto, 2-Methylvalerate/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
mmol/mol creatinine |
|
|
|
|
|
|
CHEM |
|
59376-4 |
|
|
|
|
Both |
|
|
|
0 |
3-Keto, 2-Methylvalerate/Creat Ur-sRto |
|
|
|
N |
|
Chemistry; CR; Crea; Creat; II; III; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.32 |
|
|
|
|
|
|
|
mmol/mol{creat} |
|
|
|
0 |
| 59377-2 |
2-Methylacetoacetate/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
2-Methylacetoacetate/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
mmol/mol creatinine |
|
|
|
|
|
|
CHEM |
|
59377-2 |
|
|
|
|
Both |
|
|
|
0 |
2-Methylacetoacetate/Creat Ur-sRto |
|
|
|
N |
|
2-Methylacetoacetic acid; Chemistry; CR; Crea; Creat; II; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.73 |
2.32 |
|
|
|
|
|
|
|
mmol/mol{creat} |
|
|
|
0 |
| 59378-0 |
Amikacin^post dialysis |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Amikacin [Mass/volume] in Serum or Plasma --post dialysis |
|
MIN |
DefinitionDescription |
|
|
mg/L |
|
|
|
|
|
|
DRUG/TOX |
|
59378-0 |
|
|
|
|
Both |
|
|
|
0 |
Amikacin p dialysis SerPl-mCnc |
|
|
|
N |
|
After; Amikin; Aminoglycosides; Dialy; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; p dialysis; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.32 |
|
|
|
|
|
|
|
mg/L |
|
|
|
0 |
| 59379-8 |
Gentamicin^post dialysis |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Gentamicin [Mass/volume] in Serum or Plasma --post dialysis |
|
MIN |
DefinitionDescription |
|
|
mg/L |
|
|
|
|
|
|
DRUG/TOX |
|
59379-8 |
|
|
|
|
Both |
|
|
|
0 |
Gentamicin p dialysis SerPl-mCnc |
|
|
|
N |
|
After; Aminoglycosides; c213; Dialy; DRUG/TOXICOLOGY; Drugs; Garamycin; Genirr; Genj; Gent; Level; Mass concentration; p dialysis; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.32 |
|
|
|
|
|
|
|
mg/L |
|
|
|
0 |
| 5938-6 |
Benzoylecgonine |
PrThr |
Hair |
Pt |
Ord |
|
|
ACTIVE |
Benzoylecgonine [Presence] in Hair |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
5938-6 |
|
|
|
|
Both |
|
|
|
0 |
BZE Hair Ql |
|
|
|
|
|
BEC; BEG; Benz; Benzoylec; BZE; Cocaine degradation production; Cocaine metabolite; Crack metabolite; DRUG/TOXICOLOGY; Drugs; Har; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen |
2.56 |
1.0d |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 59380-6 |
Tobramycin^post dialysis |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Tobramycin [Mass/volume] in Serum or Plasma --post dialysis |
|
MIN |
DefinitionDescription |
|
|
mg/L |
|
|
|
|
|
|
DRUG/TOX |
|
59380-6 |
|
|
|
|
Both |
|
|
|
0 |
Tobramycin p dialysis SerPl-mCnc |
|
|
|
N |
|
After; Aminoglycosides; Dialy; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; NEBCIN; NEBDIN; p dialysis; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; TOBJ; TOBRA |
2.7 |
2.32 |
|
|
|
|
|
|
|
mg/L |
|
|
|
0 |
| 59381-4 |
Vancomycin^post dialysis |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Vancomycin [Mass/volume] in Serum or Plasma --post dialysis |
|
MIN |
DefinitionDescription |
|
|
mg/L |
|
|
|
|
|
|
DRUG/TOX |
|
59381-4 |
|
|
|
|
Both |
|
|
|
0 |
Vancomycin p dialysis SerPl-mCnc |
|
|
|
N |
|
After; c162; Dialy; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; p dialysis; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; VANC; Vancocin; Vancor |
2.7 |
2.32 |
|
|
|
|
|
|
|
mg/L |
|
|
|
0 |
| 59382-2 |
Aspergillus versicolor Ab.IgG |
MCnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Aspergillus versicolor IgG Ab [Mass/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
mg/L |
|
|
|
|
|
|
ALLERGY |
|
59382-2 |
|
|
|
|
Both |
|
|
|
0 |
A versicolor IgG-mCnc |
|
|
|
N |
|
A versicolor; ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Asperg; Aspergil; Aspergilis; Aspergilla; Aspergillin; Aspergillosis; Aspergils; Aspergilus; Autoantibodies; Autoantibody; Farmers lung; Gm25; Immune globulin G; Immunoglobulin G; Level; m019; m19; m25; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; RGm25; Rm215; Serum; SR |
2.73 |
2.32 |
|
|
|
|
|
|
|
mg/L |
|
|
|
0 |
| 59383-0 |
Hydroxyproline/Creatinine |
MRto |
Urine |
2H |
Qn |
|
|
ACTIVE |
Hydroxyproline/Creatinine [Mass Ratio] in 2 hour Urine |
|
MIN |
DefinitionDescription |
|
|
mg/g creatinine |
|
|
|
|
|
|
CHEM |
|
59383-0 |
|
|
|
|
Both |
|
|
|
0 |
OH-Proline/Creat 2h Ur |
|
|
|
N |
|
120 min; 120 minutes; 120min; 2 hours; 2HR; Chemistry; CR; Crea; Creat; Hydroxylproline; Hydroxyprol; Hydroxy-proline; Hydrxprol; Hydrxproln; Hydrxyprln; Hyp; Mass concentration ratio; Mass ratio; MCRto; Ohpro; OH-Proline; QNT; Quan; Quant; Quantitative; UA; UCr; UR; Urn |
2.7 |
2.32 |
|
|
|
|
|
|
|
mg/g{creat} |
|
|
|
0 |
| 59384-8 |
Acetaminophen |
PrThr |
Urine |
Pt |
Ord |
Screen |
|
ACTIVE |
Acetaminophen [Presence] in Urine by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
59384-8 |
|
Screen |
|
|
Both |
|
|
|
0 |
APAP Ur Ql Scn |
|
|
|
N |
|
ACET; Acetamidophenol; Acetaminoph; Acetominophen; Addiction; APAP; c209; C55; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Hepatology; Hydroxyacetanilide; Illicit; Liver; N-(4-Hydroxyphenyl)acetanilide; N-Acetyl-p-aminophenol; Ordinal; p-Acetamidophenol; Paracetamol; p-Hydroxyacetanilide; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; Tylenol; u209; UA; UR; Urn |
2.73 |
2.32 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 59385-5 |
Nitrogen |
MCnt |
Stool |
Pt |
Qn |
Infrared spectroscopy |
|
ACTIVE |
Nitrogen [Mass/mass] in Stool by Infrared spectroscopy |
|
MIN |
DefinitionDescription |
|
|
g/100 g |
|
|
|
|
|
|
CHEM |
|
59385-5 |
|
Infrared spectroscopy |
|
|
Observation |
|
|
|
0 |
N2 Stl IR-mCnt |
|
|
|
N |
|
Bowel movement; Chemistry; Faecal; Faeces; Fecal; Feces; Infared spectoscopy; IR; Mass Content; N; N2; Nit; Point in time; QNT; Quan; Quant; Quantitative; Random; Stl; Stool = Fecal |
2.7 |
2.34 |
|
|
|
|
|
|
|
g/(100.g) |
|
|
|
0 |
| 59386-3 |
Starch |
MCnt |
Stool |
Pt |
Qn |
Infrared spectroscopy |
|
ACTIVE |
Starch [Mass/mass] in Stool by Infrared spectroscopy |
|
MIN |
DefinitionDescription |
|
|
g/100 g |
|
|
|
|
|
|
CHEM |
|
59386-3 |
|
Infrared spectroscopy |
|
|
Both |
|
|
|
0 |
Starch Stl IR-mCnt |
|
|
|
N |
|
Bowel movement; Chemistry; Faecal; Faeces; Fecal; Feces; Infared spectoscopy; IR; Mass Content; Point in time; QNT; Quan; Quant; Quantitative; Random; Stl; Stool = Fecal |
2.7 |
2.34 |
|
|
|
|
|
|
|
g/(100.g) |
|
|
Changed Order_Obs from 'Observation Only' to 'Both' to fit current order use cases. |
0 |
| 59387-1 |
Trypanosoma cruzi Ab.IgG |
ACnc |
Ser |
Pt |
Qn |
IA |
|
ACTIVE |
Trypanosoma cruzi IgG Ab [Units/volume] in Serum by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
Index |
|
|
|
|
|
|
MICRO |
|
59387-1 |
|
IA |
|
|
Both |
|
|
|
0 |
T cruzi IgG Ser IA-aCnc |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Chagas disease; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; MEIA; Microbiology; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR; SUDS; T cruzi; Trypanosomiasis; Trypanosomosis |
2.73 |
2.32 |
|
|
|
|
|
|
|
{Index_val} |
|
|
The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 59388-9 |
Taenia solium larva DNA |
PrThr |
CSF |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Taenia solium larva DNA [Presence] in Cerebral spinal fluid by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
59388-9 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
T sol lar DNA CSF Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Cerebral spinal fluid; Cerebrospinal Fl; Cysticercosis; Cysticercus; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Neuro; Neurology; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Strand Displacement Amplification; T sol; T sol lar; T solium; Tapeworm; TMA; Transcription mediated amplification |
2.63 |
2.32 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 59389-7 |
Androstanolone^1.5H post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Androstanolone [Mass/volume] in Serum or Plasma --1.5 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
CHAL |
|
59389-7 |
|
|
|
|
Observation |
|
|
|
0 |
Androstanolone 1.5h p chal SerPl-mCnc |
|
|
|
N |
|
1 1/2 hours; 1 1/2 HR; 1.5h p chal; 1.5Hr; 90 min; 90 minutes; 90M; 90min; After; CHEMISTRY.CHALLENGE TESTING; DHT; Dihydrotestosterone; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.34 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 5939-4 |
Benzoylecgonine |
ACnc |
Urine |
Pt |
Ord |
|
|
DEPRECATED |
Deprecated Benzoylecgonine [Presence] in Urine |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
5939-4 |
|
|
|
|
|
|
|
|
0 |
Deprecated BZE Ur Ql |
|
|
|
|
|
Arbitrary concentration; BEC; BEG; Benz; Benzoylec; BZE; Cocaine degradation production; Cocaine metabolite; Crack metabolite; DRUG/TOXICOLOGY; Drugs; Ordinal; Point in time; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.36 |
1.0d |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 59390-5 |
Neuronal nuclear Ab |
Titr |
Ser |
Pt |
SemiQn |
IF |
|
ACTIVE |
Neuronal nuclear Ab [Titer] in Serum by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
SERO |
|
59390-5 |
|
IF |
|
|
Both |
|
|
|
0 |
Hu Ab Titr Ser IF |
|
|
|
N |
|
ABS; Aby; ACIF; ANA; ANF; ANNA; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Antinuclear antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); FA; FANA; Fluorescent antibody; Fluoresent; Hu; IFA; Immune fluorescence; Immunoflour; Immunofluor; Immunofluorescence; NA; Neuro; Neurology; Nuc; Oncology; Point in time; Random; Serology; Serum; SmQn; SR; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Ttr |
2.75 |
2.32 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 59391-3 |
Prunus persica recombinant (rPru p) 3 Ab.IgE |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Peach recombinant (rPru p) 3 IgE Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
kIU/L |
|
|
|
|
|
|
ALLERGY |
|
59391-3 |
|
|
|
|
Both |
|
|
|
0 |
Peach (rPru p) 3 IgE Qn |
|
|
|
N |
|
ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; f095; f420; f95; III; Immune globulin E; Immunoglobulin E; P prime; Peach; Peach (rPru p) 3; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.7 |
2.32 |
|
|
|
|
|
|
|
k[IU]/L |
|
|
|
0 |
| 59392-1 |
Hydroxyproline |
MCnc |
Urine |
24H |
Qn |
|
|
ACTIVE |
Hydroxyproline [Mass/volume] in 24 hour Urine |
|
MIN |
DefinitionDescription |
|
|
mg/L |
|
|
|
|
|
|
CHEM |
|
59392-1 |
|
|
|
|
Both |
|
|
|
0 |
OH-Proline 24h Ur-mCnc |
|
|
|
N |
|
1 day; 24 hours; 24HR; Chemistry; Hydroxylproline; Hydroxyprol; Hydroxy-proline; Hydrxprol; Hydrxproln; Hydrxyprln; Hyp; Level; Mass concentration; Ohpro; OH-Proline; QNT; Quan; Quant; Quantitative; UA; UR; Urn |
2.34 |
2.32 |
|
|
|
|
|
|
|
mg/L |
|
|
|
0 |
| 59393-9 |
Trypanosoma cruzi Ab.IgG |
Titr |
Ser |
Pt |
SemiQn |
IF |
|
ACTIVE |
Trypanosoma cruzi IgG Ab [Titer] in Serum by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
59393-9 |
|
IF |
|
|
Both |
|
|
|
0 |
T cruzi IgG Titr Ser IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; Chagas disease; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin G; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Infectious Disease; InfectiousDisease; Microbiology; Point in time; Random; Serum; SmQn; SR; T cruzi; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Trypanosomiasis; Trypanosomosis; Ttr |
2.75 |
2.32 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 59394-7 |
Glomerular basement membrane Ab |
ACnc |
Ser |
Pt |
Qn |
IA |
|
ACTIVE |
Glomerular basement membrane Ab [Units/volume] in Serum by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
arb U/mL |
|
|
|
|
|
|
SERO |
|
59394-7 |
|
IA |
|
|
Both |
|
|
|
0 |
GBM Ab Ser IA-aCnc |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Basem; Basemt; BM; EIA; ELFA; ELISA; Enzyme immunoassay; GBM; Glom; Goodpastures; IAA; Kidney; MEIA; Nephrology; Point in time; QNT; Quan; Quant; Quantitative; Random; Renal; Serology; Serum; SR; SUDS |
2.73 |
2.32 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 59395-4 |
Latex recombinant (rHev b) 9 Ab.IgE |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Latex recombinant (rHev b) 9 IgE Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
kIU/L |
|
|
|
|
|
|
ALLERGY |
|
59395-4 |
|
|
|
|
Both |
|
|
|
0 |
Latex (rHev b) 9 IgE Qn |
|
|
|
N |
|
ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Hevea braziliensis; Immune globulin E; Immunoglobulin E; k082; k222; k82; Latex (rHev b) 9; Ltx; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.7 |
2.32 |
|
|
|
|
|
|
|
k[IU]/L |
|
|
|
0 |
| 59396-2 |
Echovirus Ab.IgM |
ACnc |
CSF |
Pt |
Qn |
IA |
|
ACTIVE |
Echovirus IgM Ab [Units/volume] in Cerebral spinal fluid by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
Index |
|
|
|
|
|
|
MICRO |
|
59396-2 |
|
IA |
|
|
Both |
|
|
|
0 |
ECV IgM CSF IA-aCnc |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; Echo; Echo virus; ECV; EIA; ELFA; ELISA; Enzyme immunoassay; EV; IAA; ID; Immune globulin M; Immunoglobulin M; Infectious Disease; InfectiousDisease; MEIA; Microbiology; Neuro; Neurology; Point in time; QNT; Quan; Quant; Quantitative; Random; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; SUDS |
2.7 |
2.32 |
|
|
|
|
|
|
|
{Index_val} |
|
|
The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 59397-0 |
Echovirus Ab.IgG |
ACnc |
CSF |
Pt |
Qn |
|
|
ACTIVE |
Echovirus IgG Ab [Units/volume] in Cerebral spinal fluid |
|
MIN |
DefinitionDescription |
|
|
Index |
|
|
|
|
|
|
MICRO |
|
59397-0 |
|
|
|
|
Both |
|
|
|
0 |
ECV IgG CSF-aCnc |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; Echo; Echo virus; ECV; EV; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; Microbiology; Neuro; Neurology; Point in time; QNT; Quan; Quant; Quantitative; Random; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid |
2.7 |
2.32 |
|
|
|
|
|
|
|
{Index_val} |
|
|
|
0 |
